Conatus Pharma readies equity offering; shares down 18% premarket

|About: Conatus Pharmaceuticals (CNAT)|By:, SA News Editor

Conatus Pharmaceuticals (NASDAQ:CNAT) slumps 18% premarket on average volume in response to its pending public offering of common stock. Price, volume and terms have yet to be announced.

Net proceeds will fund pipeline expansion and provide an exit for Advent Private Equity by virtue of purchasing 2,166,836 shares of common stock currently held by the investor.

Subscribe for full text news in your inbox